Beta Bionics Inc(BBNX) - 2025 Q4 - Annual Report

Financial Performance and Risks - The company generated all of its revenue from the sales of the iLet and related single-use products, with limited brand recognition in the medical industry for T1D treatment [202]. - The top four DME distributors accounted for approximately 52% of total sales for the year ended December 31, 2025, indicating significant customer concentration risk [203]. - As of December 31, 2025, the company had cash, cash equivalents, and short-term investments totaling $219.2 million, with net proceeds from the IPO and private placement amounting to approximately $206 million [207]. - The company estimates that its current funds will be sufficient to cover operating expenses and capital expenditures through the first half of 2028, based on current assumptions [207]. - The company may need to raise additional funds in the future, which may not be available on acceptable terms, impacting its business strategy [209]. - The total addressable market for the iLet may be smaller than anticipated, potentially limiting the company's ability to sell current and future products [221]. - The company faces risks related to regulatory actions, competitive pricing, and market conditions that could adversely impact sales and operations [204]. - Demand for the iLet exceeded initial forecasts, leading to backorders, but these did not materially impact financial results [227]. - The company has increased inventory levels of the iLet to mitigate unpredictability in demand, but failure to meet demand could harm customer relationships and revenue [227]. - The company faces intense competition from larger firms with greater financial resources, established relationships, and larger distribution networks, which may hinder its market penetration [223]. Product Development and Regulatory Challenges - The company is focusing on the commercialization of the iLet as an automated insulin dosing system for Type 1 Diabetes (T1D) and plans to expand its use for insulin-dependent Type 2 Diabetes (T2D) [250]. - The FDA has mandated a one-year post-market surveillance study for the iLet, requiring enrollment of 1,875 users and completion by June 2027 [276][277]. - The regulatory approval process for new product candidates is lengthy and uncertain, with the 510(k) clearance process typically taking 3 to 12 months [280]. - The company is developing a bihormonal system for the iLet, which will require separate regulatory approvals for both insulin and glucagon components [271]. - Modifications to the iLet may require new marketing authorizations or clearances, which could delay commercialization efforts [281]. - The company is subject to potential enforcement actions if the iLet does not meet safety and effectiveness standards as determined by the FDA [276]. - The company may face delays or inability to obtain marketing authorization for its iLet or other investigational devices if third-party collaborators fail to meet their contractual duties or regulatory obligations [366]. Clinical Trials and Research - Clinical trials are expensive and time-consuming, with uncertain outcomes, and delays in these trials could materially affect development costs and marketing authorization timelines [285]. - Patient enrollment in clinical trials is influenced by various factors, including trial protocol and competing studies, which could delay trial completion [290]. - The company may need to conduct additional clinical trials if initial results are not positive, leading to increased costs and potential delays [295]. - The company reports rates of severe hypoglycemia and DKA similar to those of other AID systems currently on the market, indicating comparable safety profiles [300]. - The company has completed over 20 pre-pivotal trials testing the iLet algorithms to enhance its learning capabilities [312]. Supply Chain and Manufacturing Risks - The company relies on international suppliers for significant quantities of iLet components, particularly from China, and changes in trade policies could materially increase manufacturing costs [262]. - The current single manufacturing facility in Irvine, California, poses risks related to potential disruptions from disasters, which could delay product availability and harm the company's reputation [342]. - The company relies on a limited number of suppliers for critical components of the iLet, including infusion sets, cartridge connectors, pump motors, and boards, which poses risks of production delays and revenue loss if any supplier fails to meet demand [344]. - Currently, the company does not have long-term supply agreements with most suppliers, purchasing components on a purchase order basis, which increases vulnerability to supply disruptions [346]. - The complexity of the iLet's design and manufacturing process may lead to defects that could increase costs and reduce revenue, impacting overall business performance [352]. Cybersecurity and Data Privacy - Cybersecurity threats pose risks to the company's operations, including potential disruptions and loss of sensitive data, which could harm revenue and reputation [237]. - The FDA has warned that insulin pumps, including the iLet products, may have cybersecurity vulnerabilities that could be exploited by hackers, posing risks to patients with diabetes [245]. - The company has experienced unsuccessful phishing attempts in the past and anticipates continued threats that could disrupt operations and compromise sensitive information [246]. - The company faces potential legal and financial repercussions from violations of data privacy laws, including the California Consumer Privacy Act (CCPA), which allows for significant statutory damages [395]. - The company must navigate evolving data privacy laws, which may increase compliance costs and legal risks associated with handling sensitive information [388]. Compliance and Legal Risks - The company is subject to various healthcare laws and regulations, including the federal Anti-Kickback Statute and the False Claims Act, which could expose it to significant penalties and reputational harm [380]. - The company must adhere to Medicaid rebate requirements and other pricing regulations under the U.S. Omnibus Budget Reconciliation Act of 1990 and the Affordable Care Act [383]. - The company is required to report breaches of unsecured protected health information (PHI) within 60 days, with potential civil and criminal penalties for violations of HIPAA [392]. - The company is prohibited from marketing the iLet for off-label uses, and any promotional activities deemed as such by the FDA could lead to regulatory actions [379]. - The company is subject to ongoing regulatory obligations and may incur significant additional expenses if it fails to comply with applicable regulatory requirements, which could adversely affect its business and financial condition [368].